Short answer
Generate Biomedicines Inc (GENB) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Generate Biomedicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- GB-0895 Phase 3 asthma trials evaluate 300 mg every 26 weeks, with six-month biomarker suppression supporting twice-yearly dosing
- Zealand deal adds $30 million upfront, up to $35 million early milestones, and nearly $1.2 billion potential milestones plus tiered royalties
- Cash, equivalents, and securities $404.2 million at September 30, with runway into first half 2028 including Zealand payment
- Third-quarter revenue fell to $4.2 million from $9.6 million, while R&D rose to $82.3 million on Phase 3 investment
- Net loss widened to $87.7 million from $60.0 million, highlighting continued cash burn despite partnership funding
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Generate Biomedicines Inc 8-K filings
Get the next GENB 8-K as it lands
Follow GENB for push alerts, or ask the research agent what this filing means.